Inhibition of Trimethylamine N-Oxide Attenuates Neointimal Formation Through Reduction of Inflammasome and Oxidative Stress in a Mouse Model of Carotid Artery Ligation
Overview
Authors
Affiliations
Trimethylamine-N-oxide (TMAO) is a metabolite generated from dietary choline, betaine, and l-carnitine, after their oxidization in the liver. TMAO has been identified as a novel independent risk factor for atherosclerosis through the induction of vascular inflammation. However, the effect of TMAO on neointimal formation in response to vascular injury remains unclear. This study was conducted using a murine model of acutely disturbed flow-induced atherosclerosis induced by partial carotid artery ligation. 3,3-Dimethyl-1-butanol (DMB) was used to reduce TMAO concentrations. Wild-type mice were divided into four groups [regular diet, high-TMAO diet, high-choline diet, and high-choline diet+DMB] to investigate the effects of TMAO elevation and its inhibition by DMB. Mice fed high-TMAO and high-choline diets had significantly enhanced neointimal hyperplasia and advanced plaques, elevated arterial elastin fragmentation, increased macrophage infiltration and inflammatory cytokine secretion, and enhanced activation of nuclear factor (NF)-κB, the NLRP3 inflammasome, and endoplasmic reticulum (ER) stress relative to the control group. Mice fed high-choline diets with DMB treatment exhibited attenuated flow-induced atherosclerosis, inflammasome expression, ER stress, and reactive oxygen species expression. Human aortic smooth muscle cells (HASMCs) were used to investigate the mechanism of TMAO-induced injury. The HASMCs were treated with TMAO with or without an ER stress inhibitor to determine whether inhibition of ER stress modulates the TMAO-induced inflammatory response. This study demonstrates that TMAO regulates vascular remodeling via ER stress. Our findings demonstrate that TMAO elevation promotes disturbed flow-induced atherosclerosis and that DMB administration mitigates vascular remodeling, suggesting a rationale for a TMAO-targeted strategy for the treatment of atherosclerosis. 38, 215-233.
Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke.
Li Z, He X, Fang Q, Yin X Biomolecules. 2024; 14(11).
PMID: 39595639 PMC: 11591650. DOI: 10.3390/biom14111463.
Trimethylamine Induced Chronic Kidney Injury by Activating the ZBP1-NLRP3 Inflammasome Pathway.
Bai L, Chen Q, Li Y, Wu F, Jin M, Chen Y Physiol Res. 2024; 73(5):779-789.
PMID: 39545792 PMC: 11629947. DOI: 10.33549/physiolres.935378.
Anwar F, Al-Abbasi F, Al-Bar O, Verma A, Kumar V Inflammopharmacology. 2024; 33(1):49-68.
PMID: 39488611 DOI: 10.1007/s10787-024-01593-x.
Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies.
Qu J, Meng F, Wang Z, Xu W J Microbiol Biotechnol. 2024; 34(12):2413-2424.
PMID: 39467697 PMC: 11729380. DOI: 10.4014/jmb.2405.05019.
Cao R, Gao T, Yue J, Sun G, Yang X J Am Heart Assoc. 2024; 13(19):e034230.
PMID: 39342506 PMC: 11681451. DOI: 10.1161/JAHA.123.034230.